FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog The Sikiric Problem: One Lab, Thirty Years, Zero Trials That Matter GOP lawmakers ask RFK Jr. to make FDA unleash risky peptides like BPC 157 The Niche FDA takes first step in possible reversal of ban on some peptides The Washington Post HHS Secretary RFK Jr. just dropped major news: the FDA is removing 12 peptides from its restrictive Category 2 list reversing the 2023 crackdown that shut down compounding pharmacies and fueled